Navigation Links
ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohn's Disease at the Digestive Disease Week (DDW) 2010 Conference
Date:5/4/2010

NEW ORLEANS, May 4 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported positive data with Traficet-EN™ (CCX282-B) in the Maintenance period of PROTECT-1 (Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial-1).   Traficet-EN maintained a clinical remission rate (Crohn's Disease Activity Index (CDAI) less than 150) of approximately 50% in Crohn's patients over the course of 36 weeks, whereas in the placebo group remission decreased progressively from 50% to 31%. The difference in remission rate between the two groups was statistically significant (p=0.01) at week 36. Also, at week 36, a statistically significant percentage of patients receiving Traficet-EN versus placebo were in corticosteroid-free remission and had normalized C-reactive protein (CRP) levels.  Traficet-EN continued to be safe and well-tolerated for the entire course of the PROTECT-1 study (aggregate dosing up to one year). These data were presented today in an oral session at the Digestive Disease Week (DDW) conference in New Orleans by Satish Keshav, M.D., Ph.D., Department of Gastroenterology, John Radcliffe Hospital, Oxford University.

The results from the Maintenance period of PROTECT-1 reported here confirmed and expanded the efficacy of Traficet-EN that was observed in the preceding Induction period of the study, which was reported in 2009.

"Treatment for inflammatory diseases of the bowel including Crohn's has been woefully insufficient for far too long for such a devastating disease," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "We believe Traficet-EN represents a paradigm shift in terms of safety and efficacy for these patients, of
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
2. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
3. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
4. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
5. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 2014  Acsis Inc., the market leader for ... has recently posted an article, "Future of ... future needs for companies, extended supply chain, and ... model no longer work today.  The article explains ... of mobile technology, machine to machine (M2M) connectivity, ...
(Date:7/25/2014)... , July 25, 2014  Solanbridge Group Inc ... acquired the majority interest in Buzznbrewz.com and the Letter ... replaced with a fully executed Purchase Agreement. ... stated "We are proud to have Mr. David ... decades of experience in the private sector and developed ...
(Date:7/25/2014)... , July 25, 2014 According ... Research "Global and China Insulin Market (Rapid-Acting, Short-Acting, Intermediate-Acting, ... Size, Share, Growth, Trends and Forecast (Value and Volume), ... at USD 19.99 billion in 2012 and is expected ... to 2019 to reach USD 32.24 billion in 2019. ...
Breaking Medicine Technology:Acsis Addresses Questions on the Modern Supply Chain 2Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4
(Date:7/25/2014)... -- Women who compete in triathlons are at increased ... health problems, a new study says. "There has ... as triathlons, but little has been known until now ... issues associated with endurance training and events," study author ... System, said in a university news release. The ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Project Ninety ... episode of Innovations with Ed Begley Jr, airing later ... times TBA. , For more than four decades, Project ... Area community through its residential alcohol and substance abuse ... on Project Ninety's humble idea and how it has ...
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
(Date:7/25/2014)... La Mirada (PRWEB) July 25, 2014 ... La Mirada clinic is offering Occupational ... Medical Center is happily accepting referrals and workers’ ... at the La Mirada clinic include wound care ... training and ergonomic assessments, pre-employment screening & physicals, ...
(Date:7/25/2014)... Medical Oncology (ESMO), the leading pan-European association representing ... proposed EU General Data Protection Regulation [1] could ... burden to both doctors and cancer patients. , ... ,explicit and specific patient consent, meaning that researchers ... research is planned in order to consult their ...
Breaking Medicine News(10 mins):Health News:Female Triathletes May Face Health Problems Such as Incontinence 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 2Health News:Project Ninety to be Featured on Innovations with Ed Begley, Jr. 3Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:Is Europe putting cancer research at risk? 2
... Speaker Nancy Pelosi released the following statement praising ... Act (H.R. 3962) that will improve access to ... with HIV/AIDS. H.R. 3962 passed the House on Saturday by ... treatments have improved both health and quality of life for ...
... , CAMBRIDGE, Mass., Nov. 9 Abt ... delivering emergency management consulting and support services with three ... Federal Emergency Management Agency,s (FEMA) Office of Regional Operations, ... Washington Metropolitan Area Transit Authority (WMATA). The value ...
... Experimental Procedure for Preteen Son - , PHILADELPHIA, ... hopeful news is that pediatric survival rates have steadily improved ... survival often cause infertility. , Boys diagnosed with ... preserve their fertility: before undergoing cancer treatment, they may have ...
... Academy of Physician Assistants (AAPA), representing more than 75,000 ... States, applauds the U.S. House of Representatives for passing ... Affordable Health Care for America Act. , "We are ... the cost of health care and greatly expand coverage ...
... will use funds to move lab findings into human ... damage , ANN ARBOR, Mich., Nov. 9 Researchers ... received a $1.8 million grant to develop a novel ... patients experience pain because of damage to nerve without ...
... release is available in French . Montreal, November 9, ... female. In human bodies trillions of cells are coupled, too, and ... these don,t come in twos, they are regrouped into indistinguishable clusters. ... and illness scientists have long searched for ways to splice ...
Cached Medicine News:Health News:Pelosi Applauds Provisions in Health Bill to Improve Access to Care, Medications for People Living With HIV/AIDS 2Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 2Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 3Health News:For Young Boys With Cancer, Testicular Tissue Banking May Be Option to Preserve Fertility 4Health News:American Academy of Physician Assistants Applauds U.S. House of Representatives for Passing Health Care Reform Bill 2Health News:U-M Researchers Receive $1.8 Million Grant to Develop New Therapy for Neuropathic Pain 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: